The pharmaceutical company Pfizer announced on Monday that the initial results of a large-scale study showed that its experimental vaccine against the Covid-19 virus is 90% effective
Pfizer and its German partner, BioNTech SE, are the first drug manufacturers to achieve successful results in large-scale clinical trials on a coronavirus vaccine. The companies said they had not been able to detect any significant safety risks so far and intended to get permission later this month to make the vaccine available for emergency use in the US.
“Today is a happy day for science and humanity,” Albert Bourla, Pfizer’s chairman and chief executive officer, said in a statement. “We are reaching an important milestone in our vaccine development program at a time when the world needs it most, while the infection rate is reaching new heights, hospitals are overcrowded, and economies are struggling to get back on track.”
Pfizer aims to get permission in the US to make the emergency vaccine available to people between 16 and 85. For this, the company will have to collect two months of safety data from about half of the study’s 44,000 participants. “I’m almost ecstatic,” Bill Gruber, one of Pfizer’s top vaccine scientists, said in an interview. “This is a great day for public health and for the chance that we can all be redeemed from the circumstances in which we find ourselves.”